KR20140096771A - Pharmaceutical composition comprising Platycodin grandiflorum extract containing platycodin D - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating contact dermatitis, which comprises platycodin D-containing platycodin D as an active ingredient. The present invention relates to a pharmaceutical composition for preventing or treating contact dermatitis, And can exhibit the effect of dermatitis caused by contact with an external substance, a skin external preparation, a cosmetic composition and a health functional food.

Description

[0001] The present invention relates to a pharmaceutical composition for preventing or treating contact dermatitis, which comprises, as an active ingredient, a bellflower extract containing platycodine D,

The present invention relates to a pharmaceutical composition for preventing or treating contact dermatitis comprising Platycodin D-containing Platycodin D as an active ingredient.

In the modern society, the incidence of skin diseases including allergic contact dermatitis is greatly increased due to the increase of environmental pollution and the production of synthetic materials due to the development of industry. In addition, urban people are increasingly exposed to allergic reactions caused by various external antigens, such as ticks, dusts that increase as humidity decreases, pet hair, pollen, new fruits and foods, as the living environment changes to westernization.

Allergic reactions caused by these various antigens are considered to be one of the causes of infant asthma, atopic dermatitis, rhinitis, urticaria, eczema, etc. Antigens causing allergic contact dermatitis are increasingly encountered in everyday life Trend.

Contact dermatitis refers to all dermatitis caused by contact with external substances. It refers to allergic contact dermatitis, which occurs only in people with primary contact dermatitis caused by the stimulation of the contact substance itself and allergic reactions to contact substances. .

Allergic contact dermatitis is characterized by the appearance of redness, papules, small spots and ulcers on the localized areas where the antigen is contacted. It belongs to a delayed type hypersensitivity reaction in which symptoms are manifested by the sensitization process of allergic antigens and the re- It is an immune disease.

Allergic contact dermatitis after the contact antigen that is passed to the Langerhans (Langerhans) cells through a unique process, the antigen is delivered to the T _H cells l (Helper T cell 1) to divide the the T _H cell memory cells (memory cell ) To form a sensitizing process. When the antigen is re-sensitized, the inflammation reaction and tissue damage are induced to manifest symptoms, and many cytokines such as IgE are released during this process.

In other words, contact dermatitis is caused by an acquired immune response, which is an allergic reaction when the same substance is contacted again with a person who has previously been contacted with an antigen that has previously been contacted, , And spots. It refers to symptoms that appear on the skin over time.

Platycodon grandiflorum ) is a dicotyledonous plant, a perennial plant, about 1 m high, has no hair, has large roots, and has one or more stems and grows straight.

Flowers bloom in July or August in light blue or white, and bell-shaped flowers are a flower orchid with one petal on the tip of a stem or on the tip of a cracked branch and the flower corolla is made up of five petals. Calyxes are bell-shaped and are divided into 5 pieces. Each piece is triangular barcelial (lanceolate), and there are 5 stamens. The head of the stigma is divided into 5 branches and the lower ovary.

In one room, the part made by removing roots or juniper is used as a medicinal material, and it is wild in mountains and fields and distributed in Korea, Japan, and China.

The main pharmacological component of the bellflower is triterpenoid saponin. It has the effect of eliminating the phlegm by increasing the bronchial secretion. The saponin component which is observed only in the bellflower is calm, fever, pain, calmness, , Improvement of cholesterol metabolism, anticholinergic, anticancer effect and inhibition of gastric acid secretion.

There is a desperate need for a therapeutic agent capable of effectively alleviating the allergic reaction from natural products having a small side effect even if it is used for a long period of time for various dermatitis patients, especially contact dermatitis patients, which are gradually increasing together with environmental pollution.

Thus, the inventors of the present invention have completed the present invention by confirming that Platycodin D-containing Platycodin D is effective in relieving itching and treating inflammation of contact dermatitis.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating contact dermatitis, which comprises a platycodin D-containing platycodone extract as an active ingredient.

It is another object of the present invention to provide an external preparation for skin for preventing or treating contact dermatitis, which comprises a platycodin D-containing platycodone extract as an active ingredient.

Another object of the present invention is to provide a health functional food for improving or alleviating contact dermatitis comprising Platycodin D-containing Platycodon D as an active ingredient.

In order to achieve the above object, the present invention provides a bellflower extract containing Platycodin D, which is a pharmaceutical composition, an external preparation for skin and a composition for external application, which shows effects on dermatitis caused by contact with external substances, It can be used as a health functional food.

In order to achieve the above object, the present invention provides a bellflower extract containing Platycodin D, which is a pharmaceutical composition, an external preparation for skin and a composition for external application, which shows effects on dermatitis caused by contact with external substances, It can be used as a health functional food.

FIG. 1 is a graph showing changes in scratching behavior after application of platycodin D-containing bellflower extract to the dorsal skin of mice in which contact dermatitis was induced by DNCB.
FIG. 2 is a graph showing skin sensory evaluation after application of platycodin D-containing bellflower extract to the dorsal skin of mice in which contact dermatitis was induced by DNCB.
FIG. 3 shows the results of tissue extractions of the dorsal epidermis after platycodin D-containing bellflower extract was applied to the dorsal skin of the dorsal skin of contact dermatitis induced by DNCB, followed by hematoxylin and eosin staining, (It relates to a microscope observation image enlarged by a factor of 40 and magnified by a factor of 100, respectively.)

The present invention provides a pharmaceutical composition for preventing or treating contact dermatitis, which comprises, as an active ingredient, a bellflower extract containing Platycodin D represented by the following formula (1):

[Chemical Formula 1]

.

.

In one embodiment of the present invention, the Platycodin D compound is a kind of flavanone, and the IUPAC designation is 3? - (? - D-glucopyranosyloxy) -2 ?, 16 ?, 23,24-tetrahydroxy- OD-apio-β-D-furanosyl- (1 → 3) -O- β-D-xylopyranosyl- (1 → 4) -O-6-deoxy-olean-12-en-28- The molecular formula (Molecular Formula) is C ₅₇ H ₉₂ O ₂₈ , and the molecular weight (Molecular Weight) is 1225.32.

The platycodine D compound of the present invention can be isolated from natural products or can be prepared by a chemical synthesis method known in the art, and commercially available platycodine D compounds can be commercially obtained and used.

In one embodiment according to the present invention, the pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of contact dermatitis characterized by relieving itching.

In one embodiment according to the present invention, the pharmaceutical composition is a pharmaceutical composition for preventing or treating contact dermatitis characterized by inhibiting an inflammatory reaction.

In one embodiment according to the present invention, the pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of contact dermatitis characterized by inhibiting edema.

In one embodiment according to the present invention, the contact dermatitis is a contact dermatitis caused by contact with an external substance, and a pharmaceutical composition for preventing or treating contact dermatitis.

In addition, the pharmaceutical composition of the present invention has almost no toxicity because it is a natural product extract or a component isolated therefrom as an active ingredient, and is harmless to the human body.

In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the pharmaceutical composition is 0.0001 to 0.1% by weight of the total pharmaceutical composition. ≪ / RTI >

In one embodiment of the present invention, Platycodin D-containing bellflower extract is prepared by extracting bellflower with water or a lower alcohol having 1 to 4 carbon atoms, fermenting it, centrifuging it to remove solid content, concentrating, The present invention also relates to a pharmaceutical composition for preventing or treating contact dermatitis.

In one embodiment of the invention, bellflower (Platycodon grandiflorum ) is extracted with water or a lower alcohol having 1 to 4 carbon atoms, fermented, and centrifuged to remove solid matter; Concentrating and freeze-drying a platycodin D-containing bellflower extract for preventing or treating contact dermatitis.

In one embodiment of the present invention, a Platycodin D-containing Platycodin D represented by the following Formula 1 is characterized by providing an external preparation for skin for preventing or treating contact dermatitis:

[Chemical Formula 1]

In one embodiment of the present invention, the pharmaceutical composition relates to an external preparation for skin for prevention or treatment of contact dermatitis characterized by relieving itching.

In one embodiment of the present invention, the pharmaceutical composition is an external preparation for skin for preventing or treating contact dermatitis characterized by inhibiting an inflammatory reaction.

In one embodiment of the present invention, the pharmaceutical composition is an external preparation for skin for preventing or treating contact dermatitis characterized by inhibiting edema.

In one embodiment of the present invention, the external preparation for skin is formulated into any one selected from the group consisting of ointments, creams, lotions, liquids, dressings, patches, foams, tapes, aerosols, external powders and spraying agents .

The external preparation for skin containing the platycodine D-containing bellows extract of the present invention can be applied directly to the local surface of the skin such as an ointment, a solution (e.g., suspension, emulsion, lotion), a foaming agent, a tape agent, So long as it can be applied. The amount of the platycodin D-containing bellflower extract varies depending on the preparation. For example, it is 0.001 to 0.1 w / v% for ointments, creams, gels and lotions, 0.001 to 0.2 w / 0.001 to 0.2 w / v% in the case of the external preparation and 0.001 to 0.2 w / v% in the external preparation.

In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the pharmaceutical composition is 0.0001 to 0.1% by weight of the total pharmaceutical composition. Skin external preparation for skin.

In one embodiment of the present invention, there is provided a cosmetic composition for improving or alleviating contact dermatitis comprising Platycodin D represented by the following formula (1):

[Chemical Formula 1]

.

.

Other ingredients than the active ingredient of the formulation of the present invention may be any ingredient commonly used in external preparations. In the case of ointments, creams, gels and lotions, there may be used white petrolatum (vaseline), yellow petrolatum, lanolin, purified beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane A mechanism such as; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamitone, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, hexyllaurate, fatty acid, fatty acid ester, vegetable oil, Solvents or stabilizers such as alcohols; Tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; Curling agents such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin; Thickeners such as carboxyvinyl polymer, xanthan gum, carboxymethylcellulose and sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Stabilizers; Preservatives; Adsorption promoters; And other suitable fillers may be added.

In the case of the blowing agent, an adhesive such as a polyacrylic acid and a polyacrylic acid copolymer; A crosslinking agent such as aluminum sulfate, aluminum potassium sulfate, aluminum chloride, magnesium aluminometasilicate and dihydroxy aluminum aminoacetate; Thickening agents such as sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, sodium alginate, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Polyhydric alcohols such as glycerin, polyethylene glycol (macrogol), polyethylene glycol and 1,3-butanediol; Surfactants such as polyoxyethylene derivatives; fragrances such as l-menthol; preservatives such as p-hydroxybenzoate; Purified water; And other suitable fillers may be added.

In the case of a tape, a pressure-sensitive adhesive such as a styrene-isoprene-styrene block copolymer and an acrylate resin; Adhesive resins such as acrylic saturated hydrocarbon resins, hydrogenated rosin resins and terpene resins; Softeners such as liquid gums and liquid paraffin; Antioxidants such as dibutylhydroxytoluene; Polyhydric alcohols such as polyethylene glycol; Adsorption promoters such as oleic acid; Surfactants such as polyoxyethylene derivatives; And other suitable fillers may be added. In addition, water-absorbing polymers such as sodium polyacrylate and polyvinyl alcohol and a small amount of purified water can be added to the preparation of tapes containing water.

In the case of an aerosol agent, bases such as white petrolatum (Vaseline), yellow petrolatum, lanolin, purified beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamitone, diethyl sebacate, diisopropyl sebacate, isopropyl adipate, hexyl laurate, fatty acid, fatty acid ester, vegetable oil, aliphatic alcohol and alcohol A solvent or a stabilizer such as; Tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; Curling agents such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin, carboxyvinyl polymers such as those used in creams, gels or lotions, xanthan gum, carboxymethyl Thickeners such as cellulose and sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Stabilizers; Buffering agents; Sweetener suspension; Emulsifiers; Condiment; antiseptic; Adsorption promoters and other suitable fillers may be added.

For external powders, potato starch, rice starch, corn starch, fillers such as talc and zinc oxide, and other suitable additives may be added.

The external preparation for skin of the present invention may be prepared by mixing well-known ingredients with appropriate bases according to a well-known method for preparing external preparations, and the thus-prepared preparation is applied to lesions as required.

In one embodiment of the present invention, the cosmetic composition is characterized in that it alleviates itching. The present invention relates to a cosmetic composition for improving or alleviating contact dermatitis.

In one embodiment of the present invention, the cosmetic composition is a cosmetic composition for improving or alleviating contact dermatitis characterized by alleviating an inflammatory reaction.

In one embodiment of the present invention, the cosmetic composition is a cosmetic composition for improving or alleviating contact dermatitis characterized by alleviating edema.

In addition, the composition using the platycodine D-containing bellows extract of the present invention may contain a functional substance such as a herbal preparation to improve the fragrance of the composition or improve the contact dermatitis improving effect.

In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the cosmetic composition is 0.00001 to 1 wt% of the total weight of the cosmetic composition. The cosmetic composition for improving or alleviating contact dermatitis ≪ / RTI >

In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the cosmetic composition is 0.0001 to 0.1% by weight of the total weight of the cosmetic composition. The cosmetic composition for improving or alleviating contact dermatitis ≪ / RTI >

In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the cosmetic composition is 0.001 to 0.01 wt% of the total weight of the cosmetic composition. The cosmetic composition for improving or alleviating contact dermatitis ≪ / RTI >

The cosmetic composition of the present invention can be prepared in any formulations conventionally produced in the art and can be used in cosmetic formulations such as external ointments for skin, essence, whitening cream, lotion, emulsion, pack, general lotion, Serum, cosmetic soap, softening lotion, medicated lotion, hair tonic, whole body cleanser, oil gel and the like.

When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.

In one embodiment of the present invention, there is provided a health functional food for improving or alleviating contact dermatitis, which comprises, as an active ingredient, a Platycodin D-containing platycodin D represented by the following formula (1) do:

[Chemical Formula 1]

.

.

In one embodiment of the present invention, the health functional food is a health functional food for improving or alleviating contact dermatitis, which alleviates itching.

In one embodiment of the present invention, the health functional food is a health functional food for improving or alleviating contact dermatitis, which alleviates an inflammatory reaction.

In one embodiment of the present invention, the health functional food is a health functional food for alleviating edema.

In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the health functional food is 0.001 to 1 wt% of the total weight of the health functional food. Health functional food for.

Hereinafter, the present invention will be described in more detail with reference to the following Experimental Examples and Preparation Examples. It should be understood, however, that the same is by way of illustration and example only and is not intended to limit the scope of the present invention.

[Example 1] Method for producing platycodin D-containing bellflower extract

Standardized 1% by weight, 3% by weight, 5% by weight platycodin D-containing bellflower extract was supplied from BN C Co., Ltd., and specific preparation was as follows.

The raw material of the bellflower was extracted more than twice with water (purified water), ethanol or methanol, and the obtained extract was centrifuged after fermentation to remove solid components, followed by concentration and lyophilization to obtain respective extracts from which the solvent was removed. In order to separate and purify the single active component from the extract, the extract obtained above was completely dissolved in water, and the activity of each fraction was confirmed using RP-18, Diaion HP-20, and ion exchange gel column Only the visible fractions were obtained, and each single active component was isolated and purified by further HPLC.

○ Analysis equipment

- HPLC system: Agilent 1260 series

Column: Kinetex C ₁₈ column (2.6 탆, 4.6 mm x 100 mm, Phenomenex, Germany)

- Detector: Alltech ELSD 2000

○ HPLC and ELSD conditions

Samples were analyzed using Agilent 1260 series HPLC.

The mobile phase used was 0.15% formic acid (A), acetonitrile (B), and methanol (C), and the following conditions were used for the column: C ₁₈ column (2.6 ㎛, 4.6 mm x 100 mm, Phenomenex, Germany) And the platycodine D, which is a target substance, was analyzed by a gradient flow method.

After completion of the slurry solvent elution, post-run was performed with 0.15% formic acid (A): acetonitrile (B): methanol (C) = 75: 20: 5 (v / v) for 10 minutes to stabilize the column. At this time, the injection amount and the flow rate of the sample were adjusted to 20 μl and 0.6 ml / min.

Platycodin D samples were detected by ELSD detector. Platycodin D was quantified by setting the flow rate and temperature at 1.5 L / min and 80 ° C using nitrogen as the drying gas.

○ Standard quantitative curve of platycodine D standard

Platycodin D was accurately weighed and dissolved in 50% methanol, and then platycodin D content was determined using a standard quantitative curve using HPLC / ELSD. Calibration curve of the standard quantitative curve obtained from the standard product of platycodine D showed good linearity at y = 17.757x-643.76 (R ² = 0.999).

For standardization of the test materials, each sample was dissolved in 50% methanol to a concentration of 20 mg / ml, and impurities were removed (0.45 μm filter) and HPLC / ELSD detection was performed.

From the chromatogram obtained, the peak area ratio of platidone D to the peak area of the internal standard material was determined, and the concentration of platycodin D in the extract was determined from a previously prepared standard curve to normalize the product.

[Experimental Example 1] Induction of allergic contact dermatitis (preparation of experimental animals)

To induce allergic contact dermatitis, DNCB (2,4-dinitrochlorobenzene) was dissolved in a mixed solution of acetone and olive oil (mixing volume ratio 3: 1) to 1% as an antigen of delayed hypersensitivity reaction. 300 [mu] L of the ICR mouse was applied to 2 cm ² of the dorsal area, and the mice were first immunized. Primary immunization After 4 days of curing, 250 μl of 0.5% DNCB was applied to the dorsal area and the second immunization was performed by treating the same amount and the same amount continuously for about 2 weeks. Platycodin D-containing bellflower extracts were applied at a dose of 0.2 mg / ml once every other day, 200 μl / well to the back of the second DNCB administration.

[Experimental Example 2] Changes in scratching behavior

After the second antigen administration, video recording was performed at 24-hour intervals to check the degree of scratching caused by contact dermatitis. After the secondary application of DNCB, the back of the dorsal epidermis continued to develop, and scratching of the dorsal part of the subject continued to increase.

In the group administered with platycodin D-containing bellflower extract, it was observed that after the third administration, the scratching was gradually reduced and recovered (FIG. 1).

[Experimental Example 3] Skin sensory evaluation was carried out

After scoring 0 points for symptom free, 1 point for symptom weakness, 2 points for normal symptom, 3 points for severe symptom for these 5 items, score 5 items The sum of the scores gave a score of at least 0 (no symptoms) to a maximum of 15 (all symptoms were severe).

In the skin sensory evaluation, DNCB was applied in the contact dermatitis - induced group, the score increased gradually to over 13 points, but in the group treated with platycodine D - containing bellflower extract, (Fig. 2).

[Experimental Example 4] Changes in the thickness of dorsal epidermis (confirmed dorsal epidermal edema)

The dorsal epidermal thickness was determined by hematoxylin and eosin staining after dorsal epidermal tissue extraction. After the second application of DNCB, edema of the dorsal epidermis continuously occurred and the thickness was increased.

In the group treated with platycodin D-containing bellflower extract, edema was significantly alleviated from the third administration, and as a result, it was observed that the platycodin D-containing bellflower extract had an anti-inflammatory effect (FIG. 3).

The above components are powdered and mixed, and filled in an airtight container to prepare a powder.

The tablets are prepared by mixing the above components according to a conventional method for producing tablets and then tableting them.

The above components are mixed according to a conventional method for preparing a capsule, and then filled in a gelatin capsule to prepare a capsule.

After mixing the above components, 100 mL of 30% ethanol is added, and the mixture is dried at 60 ° C to form granules, which are filled in a capsule to prepare granules.

After mixing the above components, they are prepared according to the usual production method of pills.

(2 mL) per 1 ampoule according to a conventional injection preparation method.

Dissolving the above components in purified water according to a usual liquid preparation method, adding an appropriate fragrance, filling the bottle and sterilizing it.

quite

The oil phase part of A and the water phase part of B are completely melted by heating them at 70 占 폚. Add phase A to phase B and emulsify with emulsifier. The emulsion was cooled with a heat exchanger to obtain a cream.

quite

A milky lotion was obtained according to Production Example 1.

quite

The alcohol phase of A was added to the aqueous phase of B and solubilized to obtain a lotion.

quite

As the prescription, the emulsion was prepared by a commercial method.

quite

Lotions were prepared by the commercial method under the above prescription.

quite

The cream was prepared by the above-mentioned procedure in accordance with the above-mentioned prescription.

Claims (20)

A pharmaceutical composition for preventing or treating contact dermatitis comprising, as an active ingredient, a bellflower extract containing Platycodin D represented by the following formula (1):
[Chemical Formula]

.
The method according to claim 1,
A pharmaceutical composition for preventing or treating contact dermatitis, wherein said pharmaceutical composition alleviates itching.
The method according to claim 1,
Wherein said pharmaceutical composition inhibits an inflammatory reaction.
The method according to claim 1,
Wherein said pharmaceutical composition inhibits edema. ≪ RTI ID = 0.0 > 21. < / RTI >
The method according to claim 1,
Wherein the contact dermatitis is contact dermatitis due to contact with an external substance.
The method according to claim 1,
A pharmaceutical composition for preventing or treating contact dermatitis, wherein the bellflower extract containing Platycodin D in the pharmaceutical composition is 0.0001 to 0.1% by weight of the total pharmaceutical composition.
The method according to claim 1,
Platycodin D-containing bellflower extract is prepared by extracting Platycodon grandiflorum with water or a lower alcohol having 1 to 4 carbon atoms, fermenting it, centrifuging it to remove solid content, concentrating it, and lyophilizing it ≪ / RTI > or a pharmaceutically acceptable salt thereof, for the prophylaxis or treatment of contact dermatitis.
Platycodon grandiflorum ) is extracted with water or a lower alcohol having 1 to 4 carbon atoms, fermented, and centrifuged to remove solid matter; And
Concentrating and lyophilizing the platycodin D-containing bellflower extract for preventing or treating contact dermatitis.
9. The method of claim 8,
Wherein the lower alcohol is methanol or ethanol. ≪ RTI ID = 0.0 > 11. < / RTI >
An external preparation for skin for preventing or treating contact dermatitis comprising, as an active ingredient, a bellflower extract containing Platycodin D represented by the following formula (1)
[Chemical Formula 1]

.
11. The method of claim 10,
Wherein said pharmaceutical composition alleviates itching. ≪ RTI ID = 0.0 > 11. < / RTI >
11. The method of claim 10,
Wherein said pharmaceutical composition inhibits an inflammatory reaction. ≪ RTI ID = 0.0 > 11. < / RTI >
11. The method of claim 10,
Wherein the pharmaceutical composition inhibits edema. ≪ RTI ID = 0.0 > 11. < / RTI >
11. The method of claim 10,
Wherein the external preparation for skin is any one selected from the group consisting of an ointment, a cream, a lotion, a liquid, a dressing, a patch, a foaming agent, a tape agent, an aerosol agent, Therapeutic skin external preparation.
11. The method of claim 10,
Wherein the platycodin D-containing platycodone extract is 0.0001 to 0.1 wt% of the total weight of the pharmaceutical composition.
A health functional food for improving or alleviating contact dermatitis comprising, as an active ingredient, a bellflower extract containing platycodin D represented by the following formula 1:
[Chemical Formula 1]

.
17. The method of claim 16,
Wherein said health functional food alleviates itching. ≪ RTI ID = 0.0 > 18. < / RTI >
17. The method of claim 16,
Wherein said health functional food alleviates an inflammatory reaction.
17. The method of claim 16,
Wherein said health functional food alleviates edema. ≪ RTI ID = 0.0 > 18. < / RTI >
17. The method of claim 16,
Wherein said Platycodin D-containing Platycodin powder is 0.001 to 1% by weight of the total weight of the health functional food.

Images